Table 3.

Drug treatment registered at baseline (before change) by class

Monotherapy (n = 186)		Co-therapy with 2 drugs (n = 150)		Polytherapy (> 2 drugs) (n = 135)
Drug	N (%)	Drugs	N (%)	Drugs	N (%)
Haloperidol	45 (24.2)	Other typical/atypical	15 (10.0)	Haloperidol/other typicals/other AC	11 (8.2)
Valproate	31 (16.7)	Haloperidol/Lithium	12 (8.0)	Haloperidol/other typicals/Valproate	11 (8.2)
Lithium	27 (14.5)	Olanzapine/Valproate	10 (6.7)	Haloperidol/other typicals/Lithium	8 (5.9)
Olanzapine	19 (10.2)	Risperidone/non-valproate AC	10 (6.7)	Other typicals/other AC/Lithium	8 (5.9)
Other typical	18 (9.7)	Other typical/Valproate	10 (6.7)	Haloperidol/other typicals	3 (2.2)
Risperidone	16 (8.6)	Risperidone/Lithium	9 (6.0)	Other typicals/Valproate/Lithium	2 (1.5)
Other AC	14 (7.6)	2 typicals	9 (6.0)	Other combinations	92 (68.1)
Quetiapine	10 (5.4)	Other typical/Lithium	8 (5.3)
Other atypical	6 (3.2)	Haloperidol/Valproate	8 (5.3)
		Lithium/non-valproate AC	8 (5.3)
		Olanzapine/Lithium	7 (4.7)
		Haloperidol/non-valproate AC	7 (4.7)
		Other combinations	37 (24.7)

AC = Anticonvulsivants;